Whether your facing an impending expiration of patent, looking to introduce or acquire a product, or you are an investor looking to drive the value of a deal, you need to be able to evaluate a pharmaceutical product portfolio against the broader drug industry landscape, anticipate potential roadblocks, and strategically determine growth areas and next steps.
Join us as we bring together thought leaders at the intersection of Intellectual Property (IP) and FDA law to discuss how strengthening your business development strategies can maximize your return on investment. We will detail the importance of taking a comprehensive IP and FDA regulatory look at your pharmaceutical product portfolio, blending reviews of the market, competitors, current clinical trials and potential barriers in order to drive strategic business decisions.
In this webinar you will:
- Gain insight into the value of a comprehensive IP/FDA regulatory pharmaceutical product analysis for driving strategic portfolio growth.
- Understand how and why IP and FDA regulatory factors can be a driver of the value of a pharmaceutical product portfolio or deal.
- Learn how to assess, identify, and capitalize on gaps in your current product portfolio.
Speakers:
Matthew is a life sciences industry lawyer who focuses his practice on achieving the business goals of clients. This includes IP related mergers and acquisitions; strategic patent prosecution; counseling with regard to FDA regulatory issues and their intersection with intellectual property; litigation in federal district court; and inter partes proceedings before the Patent Trial and Appeal Board.
Matthew has a particular expertise in the pharmaceutical, life science and medical device fields. He draws on this experience to assist clients in the identification of products as business development opportunities and to obtain and maneuver through intellectual property hurdles by coordinating due diligence, preparing patent validity, freedom-to-operate and non-infringement opinions, and resolving disputes in Federal District Court and before the U.S. Patent and Trademark Office.
Learn more about Matt’s practice
here.
Barbara helps clients make and execute on strategic decisions about FDA-regulated product approvals. She leverages her unique background, integrating science and biomedical ethics into her legal practice to create true value for her clients. Barbara frequently works alongside Buchanan’s IP attorneys to create a holistic IP/FDA strategy that takes into account the company’s patent portfolio, FDA Orange Book listings, and FDA-granted regulatory exclusivity.
Barbara assists clients with FDA regulatory matters arising before, during, and after product approval and marketing. She has worked with clients on virtually all types of FDA-regulated products, including drugs (human and veterinary), biologics, regenerative medicine (cell and gene therapies), medical devices, foods (human and veterinary), and combination products.
Learn more about Barbara’s practice
here.
Moderated by
